These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31994238)

  • 1. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study.
    Assalino M; Terraz S; Grat M; Lai Q; Vachharajani N; Gringeri E; Bongini MA; Kulik L; Tabrizian P; Agopian V; Mehta N; Brustia R; Vitali GC; Andres A; Berney T; Mazzaferro V; Compagnon P; Majno P; Cillo U; Chapman W; Zieniewicz K; Scatton O; Toso C
    Transpl Int; 2020 May; 33(5):567-575. PubMed ID: 31994238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
    Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
    Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
    Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
    JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.
    Mehta N; Guy J; Frenette CT; Dodge JL; Osorio RW; Minteer WB; Roberts JP; Yao FY
    Clin Gastroenterol Hepatol; 2018 Jun; 16(6):955-964. PubMed ID: 29175528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.
    Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A
    Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical profile and liver explant findings in patients with and without pretransplant downstaging for hepatocellular carcinoma.
    Felga G; Evangelista AS; Salvalaggio PR; Curvelo LA; Della Guardia B; Almeida MD; Afonso RC; Ferraz-Neto BH
    Transplant Proc; 2012 Oct; 44(8):2399-402. PubMed ID: 23026605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic indicators.
    Bhattacharjya S; Bhattacharjya T; Quaglia A; Dhillon AP; Burroughs AK; Patch DW; Tibballs JM; Watkinson AF; Rolles K; Davidson BR
    Dig Surg; 2004; 21(2):152-9; discussion 159-60. PubMed ID: 15166485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.
    Mahmud N; John B; Taddei TH; Goldberg DS
    Clin Transplant; 2019 Jul; 33(7):e13634. PubMed ID: 31177570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Alpha-Fetoprotein and Radiological Total Tumor Diameter as Predictors of Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    Galdino-Vasconcelos MR; Feijó MS; Ferro HM; Gomes ACR; De Almeida Santos ME; Ferreira G; Jorge F; Trevizoli N; Diaz LG; De Campos PB; Cajá G; Ullmann R; Figueira AV; Morato T; Watanabe ALC
    Transplant Proc; 2022 Jun; 54(5):1333-1340. PubMed ID: 35768294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma.
    Schraiber LDS; de Mattos AA; Zanotelli ML; Cantisani GPC; Brandão ABM; Marroni CA; Kiss G; Ernani L; Marcon PDS
    Medicine (Baltimore); 2016 Jan; 95(3):e2478. PubMed ID: 26817881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum metabolites may be useful markers to assess vascular invasion and identify normal alpha-fetoprotein in hepatocellular carcinoma undergoing liver resection: a pilot study.
    Lee CW; Yu MC; Lin G; Chiu JC; Chiang MH; Sung CM; Hsieh YC; Kuo T; Lin CY; Tsai HI
    World J Surg Oncol; 2020 Jun; 18(1):121. PubMed ID: 32493393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
    Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
    Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome.
    Shetty K; Timmins K; Brensinger C; Furth EE; Rattan S; Sun W; Rosen M; Soulen M; Shaked A; Reddy KR; Olthoff KM
    Liver Transpl; 2004 Jul; 10(7):911-8. PubMed ID: 15237377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
    Na GH; Kim EY; Hong TH; You YK; Kim DG
    HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.